Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT

Tarantino et al. (Thu,) studied this question.

www.synapsesocial.com/papers/68e62ea5b6db6435875c140d — DOI: https://doi.org/10.1200/jco.23.02170

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Enhancement of Antitumor Immunity by CTLA-4 Blockade· 1996 · 3,899 citations
2. Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial· 2021 · 138 citations
3. CTLA-4 Expression and Its Clinical Significance in Breast Cancer· 2021 · 38 citations
4. HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods· 2011 · 78 citations
5. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer· 2012 · 3,753 citations